Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss after Failure from Oral and Intratympanic Corticosteroid by Imsuwansri, Thanarath et al.
Copyright © 2012 by Korean Society of Otorhinolaryngology-Head and Neck Surgery.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
S99
Hyperbaric Oxygen Therapy for Sudden 
Sensorineural Hearing Loss after Failure from Oral 
and Intratympanic Corticosteroid
Thanarath Imsuwansri, MD
1·Pipat Poonsap, MD
2·Kornkiat Snidvongs, MD
3
1Department of Ophthalmology and Otorhinolaryngology, Burapha University Faculty of Medicine, Chon Buri; 
2Division of Preventive Medicine, 
Abhakornkiattiwong Hospital, Sattahip Naval Base, Chon Buri; 
3Department of Otolaryngology, Chulalongkorn University, Bangkok, Thailand
Case Report
INTRODUCTION
Idiopathic sudden sensorineural hearing loss (ISSNHL), defined 
as a greater than 30 dB sensorineural hearing loss occurring in 
at least three contiguous audiometric frequencies over 72 hours 
or less (1) is a disease with unknown etiology. This hearing loss 
leads to permanent morbidity. Available treatments include cor-
ticosteroid, vasodilator, immunosuppressant and antiviral medi-
cations, although controversies do still exist. To date, corticoste-
roids are the most widely accepted, but there are no worldwide 
standard practice guidelines accepted for the treatment of 
ISSNHL (2). Various regimens of corticosteroid therapy are 
available, including various types, dosages, and administration 
routes. A high dosage of oral and intravenous corticosteroids is 
believed to revive hearing impairment. Oral corticosteroids are 
currently as administered following a tapered course over a pe-
riod of 10 to 14 days (3). Nevertheless, therapy outcomes can 
not be considered satisfactory, as only 61% of patients are expe-
rience recovery (4). Intratympanic corticosteroid injections have 
been widely used to deliver corticosteroids directly into the in-
ner ear for those whom systemic steroids have not been success-
ful. Complications such as perforations of the tympanic mem-
brane, myringitis and otitis media have been reported. 
  Hyperbaric oxygen therapy (HBOT) has been shown to pro-
vide a significant additional effect when used in combination with 
a steroid therapy for ISSNHL (5). Outcomes of ISSHNL are sig-
nificantly improved in the combined therapy of HBOT with 
conventional treatment modalities (6). This case report describes 
a patient who experienced full recovery following HBOT, after 
an unsuccessful treatment attempt with oral and intratympanic 
corticosteroids. 
CASE REPORT
Clinical presentation 
A Thai 37-year-old man presented at Burapha University with a 
sudden bilateral progressive hearing loss. He had a known case 
of hypertension, well-controlled with amlodipine. He suddenly 
lost his left hearing and experienced tinnitus and aural fullness. 
A high dose of steroids (prednisolone, 60 mg/day) was adminis-
tered by the first physician. He subsequently developed a right 
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hearing loss without left ear improvement and was referred to 
the first author. He had no history of either otitis media or any 
ototoxic medication. His blood pressure was 145/85 mmHg. Ear 
examination was unremarkable. Weber testing with a 512 Hz 
tuning fork showed no hearing response by the patient in both 
ears. He was diagnosed as bilateral progressive ISSNHL. Magnet-
ic resonance imaging of the brain and the cerebropontine angle 
was unremarkable. Venereal disease research laboratory (VDRL), 
treponema pallidium hemagglutination (TPHA), and anti-human 
immunodeficiency virus (HIV) were non-reactive. Complete 
blood count found no leukocytosis and no anemia. Fasting blood 
sugar was 95 mg/dL.
Standard treatment
A high dose of oral steroid treatment (prednisolone, 60 mg/day) 
was administered by the first physician 3 days after the onset of 
the hearing loss. Audiogram was repeated after a week of stan-
dard treatment. The audiogram revealed right profound sensori-
neural hearing loss with a threshold of 78 dB and left deafness 
with a threshold of 90 dB. Administration of systemic steroids 
was then discontinued.
Salvage treatment
Intratympanic membrane steroids (methylprednisolone, 40 mg/
mL) were administered in the left ear 3 times within a week (at 
day 9, 10, 16 after the onset). The hearing level after the third 
dose showed minimal improvement for both ears. The air con-
ductive thresholds were 60 dB and 53 dB for the right and left 
ears, respectively. The bone conductive threshold was 43 dB for 
both ears. 
HBOT
As HBOT is not yet standard for sudden sensorineural hearing 
loss, it was introduced to this patient as an alternative therapy. 
With no further improvement after the last audiogram (day 16), 
the patient decided to undergo HBOT (day 36) for a salvage 
treatment after a discussion with the authors. 
  The HBOT program was scheduled for 10 sessions according 
to the US Navy treatment table (2 ATA 90 minutes) (Fig. 1). We 
used a 6-seat multi place chamber for the HBOT (Figs. 2 and 3), 
which was started at day 36 after the hearing loss onset. After 
the third session of HBOT (day 38), normal hearing returned, 
with no tinnitus in both ears. The following audiogram revealed 
normal hearing with a right threshold of 20 dB and a left thresh-
old of 30 dB. Tinnitus was evaluated to be resolved by the visual 
analog scale. The patient was sent for the 4th (day 41) and the 
5th sessions (day 42) as scheduled. The following audiogram 3 
months after the entire treatment showed normal hearing level 
with a right threshold of 22 dB and a left threshold of 20 dB.
  Audiograms and the time course are displayed in Figs. 4 and 5, 
respectively. No adverse events during or following HBOT and 
the intratympanic membrane injection were reported. 
DISCUSSION
To date, the awareness of HBOT as treatment for ISSNHL is low 
in Thailand. Whereas Navy hospitals and a few private hospitals 
Fig. 1. Treatment table hyperbaric oxygen therapy (HBOT) 45/90 
minutes. Total elapsed time: 95 minutes.
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have been equipped with a hyperbaric chamber, only a small 
number of medical schools is planning for installation of HBOT 
facilities. Effective communication between doctors and patient 
is required. Patients have the right to know both the risks and 
benefits of the treatment, particularly when non-standard alter-
native treatment options are available and if they are of the first 
cases in the country. In addition, the criteria of salvage treatments 
should be discussed in terms of time course and hearing levels. 
In this case, the authors started HBOT at the fifth week (day 36) 
after the onset of hearing loss. At this stage, spontaneous im-
provement is no longer expected, as the process of inflammation 
usually does not last beyond 2 to 3 weeks. Although the admin-
istration of intratympanic steroids (last dose given at day 16) of-
fered some benenfit, as demonstrated by the improved audiom-
etry, additional improvement after day 36 was not expected. Bi-
lateral moderate hearing loss is the other aspect in which patients 
may experience more benefit than harm from the salvage treat-
ment. 
  Although we cannot ascertain the causes of hearing loss, it may 
be related to a lack of oxygen secondary to a vascular problem 
not yet identified. HBOT involves breathing in pure oxygen from 
a specially designed chamber. This method is used to increase 
the supply of oxygen to the ear and the brain to reduce the se-
verity of a hearing loss and tinnitus (7). The HBOT in this case 
resulted in full recovery of the hearing thresholds without tinni-
tus or any complications. Others studies have demonstrated com-
parable outcomes of HBOT, supporting the results of our case 
report. Patients who received HBOT in conjunction with corti-
costeroids presented with enhanced clinical outcomes compared 
to those receiving only corticosteroids in the study by Fujimura 
et al. (5). 
  The standard regimen of HBOT for treating ISSNHL is yet to 
be defined. Our initial plan was to apply the treatment table 
45/90 (2 ATA 90 minutes) for 10 sessions. But when the patient 
demonstrated returned normal hearing with no tinnitus in both 
ears during the third and the fifth session of HBOT, the last five 
sessions were believed to be unnecessary and eventually can-
celed. The other regimen proposed by Topuz et al. (6), which in-
volvesundertaking HBOT 2.5 ATA for 90 minutes twice daily 
for the first five days and then once daily for the next fifteen 
days, also demonstrated good results. Patients over 50 years of 
age having a severe sensorineural hearing loss greater than 60 
dB and receiving HBOT without delay experienced a higher rate 
of recovery. 
  Although we know that HBOT promotes oxygenation to the 
target tissue, its exact mechanism of action is undefined. As for 
ISSNHL, the inner ear apparatus and hearing ability may be re-
vived by this mechanism. Further investigation is warranted, in-
cluding animal studies to understand the molecular and histo-
pathological aspects of HBOT and randomized control clinical 
studies. 
Fig. 4. Audiogram (A) before treatment (B) after oral corticosteroid (C) after intratympanic corticosteroid adminstration (D) after hyperbaric oxy-
gen therapy.
Fig. 5. Hearing level (dB) by time course (week) showing the dura-
tion of each treatment. HBOT, hyperbaric oxygen therapy.
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  In conclusion, HBOT may be used for idiopathic sudden sen-
sorineural hearing loss as an adjuvant therapy. It may promote 
oxygenation to the inner ear apparatus and revive hearing abili-
ty. Patients who fail to respond to oral and intratympanic steroids 
may benefit from this treatment. Further investigation is warrant-
ed, including animal studies to understand the molecular and 
histopathological aspects of HBOT and randomized control clin-
ical studies.
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